Researchers tracked data from nearly 8,000 patients evaluated with Heartflow's FDA-cleared Plaque Analysis software. Overall, the technology's Plaque Staging feature was found to provide significant value during the diagnosis and management of these patients.

The new drug from Merck was linked to several benefits for patients who are already on statins. If an oral PCSK9 inhibitor gains FDA approval, it could be a game-changer for the field of preventive medicine. 

Noninvasive coronary CT angiography is growing more and more important as time goes on, helping cardiologists make critical treatment decisions. Carlos Collet, MD, PhD, discussed the technique's potential to be a real game-changer for patient care in a new interview. 

The rise of these medications continues to be one of the biggest stories in healthcare.

Leaders from HRS and Heart Rhythm Advocates will take the stage to explore policy updates, advocacy goals for the future and much more.

As one may expect, patient satisfaction was considerably higher for individuals who did not have to fast for a minimum of six hours prior to treatment. There were no other significant differences.

Highly anticipated trial data comparing mechanical thrombectomy to anticoagulation alone for intermediate- and high-risk pulmonary embolism showed that the more aggressive strategy improved outcomes.

The new findings, presented during a late-breaking presentation, focused on 110 PAD patients treated with Shockwave Medical's Javelin Peripheral IVL Catheter.